Unraveling cocaine metabolism in patients with cocaine use disorder for the purpose of potentially improving bioanalytical tests for cocaine use - Unraveling cocaine metabolism in patients with CUD

Start Date12 Nov 2024

Sponsor / Collaborator-

NCT06443255

/ CompletedPhase 3IIT

Comparison of Cocaine, Lidocaine/xylometazoline and Saline for Intranasal Analgesia - a Blinded Triple Crossover Study

When performed by trained personnel nasotracheal intubation is a safe and effective technique for attaining a secure airway in preparation for surgery of the head and neck. The procedure can be deemed necessary due to the nature of the surgical procedure or considerations in regard to the patient's comorbidities. For a certain group of patients with expected difficult airways, the procedure is done whilst they are awake and aided by fiberoptics.
For these awake patients, extra precautions must be taken to ensure the procedure is conducted with minimal pain and discomfort. The pain and discomfort arises from the mechanical manipulation of the nasal mucosa and can be alleviated in part by means of topical analgesia as well as through decongestion, providing more space within the nasal cavity. For these purposes, several drugs in varying combinations and dosages are used, but no single drug choice is universally recommended.
Cocaine is one of these appropriate drugs. It is a magistral formula used especially due to its unique combination of both vasoconstrictive and analgesic properties. Concerns have though been raised regarding cocaine's potential toxicity and alternative medications are continuously sought after.
A combination of lidocaine and xylometazoline can also be used for preparation of the nose prior to awake nasal fiberoptic intubation. Lidocaine contributes with its analgesic effect whilst xylometazoline functions as the vasoconstrictor.
The investigators wish to compare the analgesic effects of cocaine and lidocaine/phenylephrine to each other and saline when subjectively scored on a visual analogue scale of 0-100 mm immediately after simulated awake nasal intubation on healthy volunteers.

Start Date01 Jul 2024

Sponsor / Collaborator

Rigshospitalet

NCT05809453

/ CompletedPhase 1/2IIT

Intranasal Cocaine and Temperature Regulation During Exercise

Assess the effects of intranasal cocaine on temperature regulation and whole-body sweat rate during exercise in warm environmental conditions.

Start Date01 Sep 2023

Sponsor / Collaborator

The University of Texas Southwestern Medical Center

100 Clinical Results associated with Cocaine Hydrochloride

100 Translational Medicine associated with Cocaine Hydrochloride

100 Patents (Medical) associated with Cocaine Hydrochloride

49,465

Literatures (Medical) associated with Cocaine Hydrochloride

01 Jun 2025·Addictive behaviors reports

Do we need urine drug screens in opioid addiction treatment: An observational study on self-report versus urine drug screens

Article

Author: Worster, Andrew ; Marsh, David C ; Dennis, Brittany B ; Thabane, Lehana ; Rodrigues, Myanca ; McEvoy, Alannah ; Samaan, Zainab ; Hudson, Jacqueline

Background:

The substance use crisis continues to progress. Medication for Opioid Use Disorder (MOUD) are prescribed to reduce opioid use and related harms; however, many individuals continue to use substances while on treatment. The objective of this study was to describe the temporal and demographic trends of the agreement between self-reported and urine tested substances.

Methods:

The current study is a retrospective secondary analysis of three phases of a prospective cohort study (Pilot 2011, Genetics of opioid addiction (GENOA) 2013-2017, and Pharmacogenetics of opioid substitution treatment (POST)) 2018-2022) spanning 2011-2022. We compared the self-reported substance use data for opioids, benzodiazepines, amphetamine/methamphetamine (AMP/MET), and cocaine with urine drug results. We compared the positive predictive value (PPV), false omission rate (FOR), sensitivity, and specificity between (i) different drugs; (ii) by sex, and (iii) age group at enrollment in each phase of the study using self-reported substance use at baseline and retrospective electronic health record data on urine drug screenings collected over the same time period.

Results:

Overall, the average PPV and FOR for any drug across all phases was 80.7 % and 37.9 %, respectively. Sensitivity and specificity were highest for cocaine and lowest for benzodiazepines. We found no specific trend by sex. Lastly, we found a higher sensitivity for opioids and AMP/MET in those under 25 years of age compared to other age groups. PPV increased over time for benzodiazepines, AMP/MET and cocaine and FOR was higher during the pilot and POST phases than the GENOA phase.

Conclusion:

Our study highlights the unique challenges associated with ascertaining substance use behaviour for individuals receiving MOUD, indicating many patients will accurately report substance use while others do not. It is therefore important to consider the context of the patient, and the type of the co-substance used to select patient-centred testing as indicated. Therefore, the answer to the question of do we need urine drug screen is yes in some cases.

01 Jun 2025·Addictive behaviors reports

A novel, multi-component contingency management intervention in the context of a syndemic of drug-related harms in Glasgow, Scotland: First year of the ‘WAND’ initiative

Article

Author: Priyadarshi, S ; Hunter, C ; Craik, J ; Trayner, K M A ; Campbell, J ; Smith, S ; Hutchinson, S J ; McAuley, A

Background:

To address high levels of drug-related harms among people who inject drugs (PWID) in Glasgow, a novel contingency management intervention was developed to engage high-risk PWID with four harm reduction measures (known as the WAND initiative: Wound care, Assessment of injecting, Naloxone, and Dried blood-spot test). Our aims were to assess if WAND engaged and re-engaged high-risk PWID.

Methods:

Baseline data of WAND participants (n = 831) from 1st Sept-2020 to 30th Aug-2021 were analysed. For those who took part in the first six months, extent of re-engagement was determined and, among those re-engaged, intervention coverage was compared between baseline and final engagement.

Results:

Among those who first engaged in WAND from Sept 2020-Feb 2021 (n = 546), 40 % re-engaged by Aug 2021. Compared to those who engaged once (n = 321), those who re-engaged (n = 215) within one year had higher baseline prevalence of injecting risk behaviours such as injecting daily (56 % vs 64 %, p = 0.032), injecting away from home (42 % vs 52 %, p = 0.0179), injecting cocaine (56 % vs 75 %, p < 0.001), having an SSTI (40 % vs 60 %, p < 0.001), and been prescribed naloxone (57 % vs 72 %, p < 0.001). For those who re-engaged six months to one year after initial engagement (n = 107), there was a significant increase in having a BBV test in the last six months (61 % to 81 %, p = 0.003) and carrying naloxone (22 % to 32 %, p = 0.011).

Conclusion:

WAND was able to engage and re-engage large numbers of high-risk PWID with multiple harm reduction initiatives. These findings suggest contingency management could be a useful tool for harm reduction services.

01 Jun 2025·BIOELECTROCHEMISTRY

Facile preparation of bifunctional monolayers through diazonium grafting and “click” postfunctionalization: A first step towards efficient aptasensing interfaces

Article

Author: Hanganu, Anamaria ; Onaş, Andra Mihaela ; Raicopol, Matei D ; Iovu, Horia ; Pandele, Andreea Mădălina ; Florea, Ciprian Victor ; Pilan, Luisa

Herein, we present an efficient approach for developing electrochemical aptasensing interfaces, by "click" postfunctionalization of phenylethynyl-grafted glassy carbon substrates with mixed monolayers containing biorecognition elements and phosphorylcholine zwitterionic groups. Typically, controlling the composition of multicomponent surface layers by grafting from a mixture of aryldiazonium salts is challenging due to differences in their chemical reactivity. Our approach circumvents this issue by employing the electrochemical reduction of a single aryldiazonium salt containing a silyl-protected alkyne group followed by deprotection, to create phenylethynyl monolayers which can subsequently accommodate the concurrent immobilization of bioreceptors and zwitterionic groups through "click" postfunctionalization. We show that the surface ratio of the components in the bifunctional monolayers, estimated through XPS and electrochemical methods, can be accurately controlled by adjusting the mole ratio of the corresponding azide reagents in the "click" coupling solution. Moreover, electrochemical impedance spectroscopy and fluorescence microscopy investigations on bifunctional monolayers containing ssDNA and phosphorylcholine groups reveal that they effectively prevent nonspecific protein adsorption, while maintaining sufficiently low impedance to facilitate electrochemical detection. Finally, we demonstrate that proof of concept aptasensing interfaces based on binary layers containing a ferrocene-tagged cocaine/quinine aptamer and phosphorylcholine groups exhibit a trade-off between an improved analytical response and antifouling efficiency.

200

News (Medical) associated with Cocaine Hydrochloride

06 Feb 2025

·www.globenewswire.com

Intelligent Bio Solutions expects to achieve 32.6% Gross Profit Expansion and Increased Profitability on Higher-Margin Sales

Gross profit expected to surge by 32.6% Unaudited revenue of $0.61 million for fiscal Q2 and $1.48 million for the six months ended December 31, 2024 Higher-margin cartridge sales driving profitability and long-term growth Expanding U.S. and international market presence with FDA submission and strategic partnerships NEW YORK, Feb. 06, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced its preliminary unaudited selected financial results for the fiscal second quarter and six months ended December 31, 2024. For the fiscal 2025 second quarter and six-month period, the Company anticipates: Unaudited revenue of approximately $0.61 million for the three months ended December 31, 2024.Unaudited revenue of approximately $1.48 million for the six months ended December 31, 2024.Gross profit to increase 32.6% from $0.43 million to $0.57 million for the six months ended December 31, 2024.Gross profit margin expected to increase to 38.5% from 27.7% for the six months ended December 31, 2024.The anticipated increase in gross profit and gross profit margin is driven by the Company's ongoing efforts to maximize recurring revenue from the sale of cartridges used in its Intelligent Fingerprinting Drug Screening System. Cartridge sales are expected to continue to outpace reader sales, serving as a primary source of recurring revenue with a higher profit margin. The sustained growth in gross profit and gross profit margin supports INBS' long-term financial stability and expansion. “Our strong financial performance underscores the momentum we are building. Despite quarterly fluctuations, our total calendar year revenue grew 23% year-on-year, reflecting our sustained upward trajectory. More importantly, our strategic focus on higher-margin cartridge sales is driving a significant 11-point expansion in gross profit margin, reinforcing the strength of our business model,” said Harry Simeonidis, President and CEO at Intelligent Bio Solutions. “As we continue scaling, our growing base of 400+ accounts and international expansion efforts position us for sustained profitability and long-term success.” During the fiscal second quarter, the Company submitted its 510(k) premarket notification to the FDA for its Intelligent Fingerprinting Drug Screening System and strengthened its market reach through strategic partnerships. The Company's 510(k) submission represented a key achievement as it plans to enter the multi-billion-dollar U.S. drug screening market in 2025. The strategic partnerships are expected to increase opportunities for the Company in the U.S. market and internationally, with a focus on expanding brand awareness of the Company and leveraging its proprietary fingerprint sweat-based drug screening technology to address evolving workplace and law enforcement drug testing needs in key regions. The preliminary unaudited revenue results for the fiscal second quarter and the six months ended December 31, 2024, are based on information available to management as of the date of this press release and are, therefore, subject to adjustments based on the Company's completion of its quarter-end financial close process. The Company expects to disclose financial results for the fiscal second quarter ended December 31, 2024, in its upcoming Quarterly Report on Form 10-Q, expected to be filed with the Securities and Exchange Commission during the week commencing February 10, 2025. About Intelligent Bio Solutions Inc. Intelligent Bio Solutions Inc. (NASDAQ: INBS) is a medical technology company delivering innovative, rapid, non-invasive testing solutions. The Company believes that its Intelligent Fingerprinting Drug Screening System will revolutionize portable testing through fingerprint sweat analysis, which has the potential for broader applications in additional fields. Designed as a hygienic and cost-effective system, the test screens for the recent use of drugs commonly found in the workplace, including opiates, cocaine, methamphetamine, and cannabis. With sample collection in seconds and results in under ten minutes, this technology would be a valuable tool for employers in safety-critical industries. The Company’s current customer segments outside the US include construction, manufacturing and engineering, transport and logistics firms, drug treatment organizations, and coroners. For more information, visit: http://www.ibs.inc/ Forward-Looking Statements Some of the statements in this release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. Forward-looking statements in this press release include, without limitation, Intelligent Bio Solutions Inc.’s ability to successfully develop and commercialize its drug and diagnostic tests, realize commercial benefit from its partnerships and collaborations, and secure regulatory approvals, among others. Although Intelligent Bio Solutions Inc. believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. Intelligent Bio Solutions Inc. has attempted to identify forward-looking statements by terminology, including “believes,” “estimates,” “anticipates,” “expects,” “plans,” “projects,” “intends,” “potential,” “may,” “could,” “might,” “will,” “should,” “approximately” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, included in Intelligent Bio Solutions’ public filings filed with the Securities and Exchange Commission. Any forward-looking statements contained in this release speak only as of its date. Intelligent Bio Solutions undertakes no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events. Company Contact:Intelligent Bio Solutions Inc.info@ibs.incLinkedIn | Twitter Investor & Media Contact:Valter Pinto, Managing DirectorKCSA Strategic CommunicationsPH: (212) 896-1254INBS@kcsa.com

Financial Statement

01 Feb 2025

·www.globenewswire.com

Intelligent Bio Solutions Partners with IVY Diagnostics to Expand in Europe’s $3.6 Billion Drug Screening Market and in Middle Eastern Regions

Jan. 28, 2025 -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced the strengthening of its foothold throughout Europe and the Middle East through its partnership with IVY Diagnostics Srl (“IVY Diagnostics”). As a key distributor, IVY Diagnostics is playing an integral role in expanding the adoption of INBS' Intelligent Fingerprinting Drug Testing Solution across Europe and the Middle East, with a particular focus on drug rehabilitation and law enforcement applications. According to Grand View Research, the European and Middle Eastern drug screening markets are projected to grow significantly by 2030, with Europe expected to reach $3.6 billion1 and the Middle East and Africa $432.7 million2. This growing demand emphasises the strategic importance of INBS' partnership with IVY Diagnostics. IVY Diagnostics, a well-known consulting and distribution company within the diagnostics, life sciences and pharmaceutical sectors, has collaborated with another Italian distributor to secure a tender to provide INBS' drug screening technology for drug rehabilitation programs across Italy. The solution offers a non-invasive, rapid, and hygienic method for drug screening, which has been well received by rehabilitation centres aiming to enhance their testing protocols. In addition to its success in rehabilitation services, INBS' drug screening system is currently undergoing a trial with the local police force in Turin. The trial aims to explore the effectiveness of fingerprint-based drug testing in roadside screening initiatives, offering a more efficient, less invasive alternative to the traditional methods currently used. As the demand for drug screening solutions rises across Europe and the Middle East, INBS’ collaboration with IVY Diagnostics positions the Company to effectively capture new opportunities. IVY Diagnostics serves as INBS' primary contact in Europe, leveraging its extensive network of distributors and expertise in identifying and vetting new partners across key regions, including Romania, Hungary, Slovakia, Austria, and Scandinavia. The collaboration extends to the Middle East, targeting markets such as the UAE, Saudi Arabia, and Qatar. "Our strategic partnership with IVY Diagnostics plays a key role in introducing our fingerprint sweat-based drug screening technology to new markets and industries," said Doug Heath, Vice President of Global Sales at Intelligent Bio Solutions. "Their deep understanding of the regulatory landscape, coupled with their extensive connections across Europe and the Middle East, positions them as an invaluable partner in our mission to provide safer and more efficient drug testing solutions worldwide." IVY Diagnostics is enthusiastic about raising awareness around the benefits of fingerprint-based drug testing technology, working closely with stakeholders to highlight its applications in sectors requiring stringent drug testing protocols. The efforts of IVY Diagnostics align with INBS' vision to transform drug screening through innovative, non-invasive, and accessible solutions. IVY Diagnostics Srl is a dynamic company operating in the diagnostics and life sciences sectors, with a focus on Point of Care Testing (POCT) and rapid testing solutions. Since its foundation in 2013, IVY Diagnostics has grown steadily, expanding its portfolio to include proprietary and distributed diagnostic products, as well as consulting services aimed at supporting clients worldwide. The company is recognized for its commitment to innovation and quality, having launched advanced solutions such as the easyTOX™ drug detection system and established a strong presence in international markets. IVY Diagnostics combines flexibility and customer focus to deliver impactful solutions for healthcare professionals and organizations globally. Intelligent Bio Solutions Inc. (NASDAQ: INBS) is a medical technology company delivering innovative, rapid, non-invasive testing solutions. The Company believes that its Intelligent Fingerprinting Drug Screening System will revolutionize portable testing through fingerprint sweat analysis, which has the potential for broader applications in additional fields. Designed as a hygienic and cost-effective system, the test screens for the recent use of drugs commonly found in the workplace, including opiates, cocaine, methamphetamine, and cannabis. With sample collection in seconds and results in under ten minutes, this technology would be a valuable tool for employers in safety-critical industries. The Company’s current customer segments outside the US include construction, manufacturing and engineering, transport and logistics firms, drug treatment organizations, and coroners. ____________________ Hyperlinks and website references in this release are provided for convenience only and do not incorporate the referenced content into this release. 1 Grand View Research. Europe Drug Screening Market Size & Outlook, 2023-2030. Available at: https://www.grandviewresearch.com/horizon/outlook/drug-screening-market/europe 2 Grand View Research. Middle East and Africa Drug Screening Market Size & Outlook. Available at: https://www.grandviewresearch.com/horizon/outlook/drug-screening-market/mea The content above comes from the network. if any infringement, please contact us to modify.

Diagnostic Reagents

20 Jan 2025

·www.drugs.com

Ketamine Use Is on the Rise in U.S.

MONDAY, Jan. 20, 2025 -- Many more Americans are turning to ketamine for kicks, a new study reports. Recreational use of the anesthetic drug among U.S. adults increased 40% between 2021 and 2022, researchers say. That follows a nearly 82% increase in ketamine use from 2015 to 2019, results show. The more recent increase occurred mainly among young adults 26 to 34, as well as in people with a college degree, researchers found. “These findings are consistent with other research indicating increased use among nightclub attendees in New York City along with increasing law enforcement seizures of illicit ketamine in the U.S.,” wrote the research team led by Dr. Kevin Yang , a third-year resident physician in psychiatry at the University of California-San Diego School of Medicine. Ketamine -- also known as “Special K” or Super K” -- is typically used an anesthetic for people and animals. In 2019, the U.S. Food and Drug Administration (FDA) approved the use of a nasal spray ketamine derivative called esketamine ( Spravato ) to treat depression in adults, according to the National Institute on Drug Abuse (NIDA). Ketamine can cause changes in how people perceive reality, the NIDA says. Users might feel like they are floating outside their bodies or dissolving into their environment. “At higher doses, a person may experience extreme detachment from their body and reality, which is called being in a k-hole,” the NIDA’s website on ketamine says. A ketamine overdose can cause potentially life-threatening slow and shallow breathing, particularly when combined with other drugs. Long-term use is linked to memory problems, depression and anxiety. For the new study, researchers analyzed data gathered between 2015 and 2022 by an annual federal survey on drug use and health. They found that the surge in ketamine use during the 2010’s was largely associated with people suffering depression. Adults with depression were 80% more likely to have used ketamine between 2015 and 2019, possibly self-medicating their mood disorder. But the increase between 2021 and 2022 occurred only in people without depression, results show. “These findings suggest a potential shift in the relationship between ketamine use and depression, such that recreational use became less associated with depression over time,” researchers wrote in study published recently in the Journal of Affective Disorders . People with college degrees were more than twice as likely to have used ketamine during the latest surge, compared to those with a high school education or less, results show. And young adults 26 to 34 were 66% more likely to have used ketamine than 18- to 25-year-olds, researchers found. “In particular, ketamine use was highly associated with the use of other ‘club drugs,' such as ecstasy/MDMA, GHB, and cocaine,” researchers wrote. “These findings suggest that ketamine use often occurs in the context of poly-club-drug use.” These shifts provide public health officials with clues for responding to increasing ketamine use. “Prevention outreach should be expanded to settings like colleges where younger adults may be at heightened risk, providing education on the harms of polydrug use, particularly in combination with opioids,” the researchers concluded. Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.

Drug ApprovalClinical ResultNDA

100 Deals associated with Cocaine Hydrochloride

External Link

KEGG	Wiki	ATC	Drug Bank
D02182	Cocaine Hydrochloride	S01HA01 S02DA02 N01BC01	DB00907

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Anesthesia	US	Noden Pharma DACStartup	14 Dec 2017

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Cocaine-Related Disorders	Phase 2	US	Biotie Therapies Oy	01 Jun 2008

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ATS2024	Not Applicable	-	-	Cocaine	ghamupemnz(xnxzspjtqe) = showed a Wellens' pattern with ST-elevation and biphasic T-waves in lead V2-V3 kmseczlpjs (bruzafualf ) View more	-	19 May 2024
P2-4.012 (AAN2024)	Not Applicable	Ischemic stroke	-	Cocaine users	bzbyljhjsj(vglhvhddit) = gcbswzhdqs zyjcynodqa (ahjihomroe )	Negative	09 Apr 2024
				Non-cocaine users	bzbyljhjsj(vglhvhddit) = issjnsrjxd zyjcynodqa (ahjihomroe )
SAT439 (ENDO2023)	Not Applicable	Diabetic Ketoacidosis	-	Empagliflozin 25mg daily	elesrvntdx(zhvlailxsb) = Due to patients’ severe acidosis and concerns for cardiac arrest, he was intubated for airway protection and admitted to the ICU for further management. DKA protocol was initiated and treatment with IV insulin, IV 5% Dextrose, 0.45% normal saline, potassium replacement, and IV bicarbonate provided until anion gap closed and acidosis resolved. Eventually, patient was successfully extubated and transferred to ward for further management and diabetic treatment optimization. qixhnvuynt (irtruoiokg ) View more	Positive	05 Oct 2023
ATS2023	Not Applicable	-	-	Cocaine inhalation	zyfpefqdzt(pbcoamjduo) = Prevention of pulmonary toxicity requires cessation of cocaine use and a referral to a substance use treatment program is advised. wcbcdzcunw (afqhwqxjsj ) View more	-	21 May 2023
ATS2023	Not Applicable	-	-	Cocaine	knegjzpsdc(mdhqkxmqmp) = gtzcyhgfip yfjlmmjmwc (edqudzpegd ) View more	-	21 May 2023
NCT01906346 (CTgov)	Early Phase 1	Cocaine-Related Disorders	9	Placebo+Cocaine (Low Value Alternative Reinforcer)	gbgmvmutbu(qsgkeucvhy) = gpazlcypit anqfqgsdzt (figcgchkpk, ezgulgxnrh - tcalzlkmds) View more	-	17 May 2019
				Placebo+Cocaine (Medium Value Reinforcer)	gbgmvmutbu(qsgkeucvhy) = fzgjkcgnnc anqfqgsdzt (figcgchkpk, ltxcfsxgiy - nkqkuwwlen) View more
NCT02383043 (CTgov)	Early Phase 1	Cocaine-Related Disorders	18	Cocaine+Sustained Release d-Amphetamine	ieclpuvtkd(xitfwqnytk) = kibzqoywfp cxdavnbeaj (tyrtqcwmce, sunkgmfzmz - miadrorayz) View more	-	11 Apr 2019
AAN2018	Not Applicable	Acute Ischemic Stroke cocaine use	-	AIS with cocaine use	exoykedbqm(ctcoqhtlgi) = mywicpaxtt agfwghizkl (jhtehnghlo ) View more	-	10 Apr 2018
				AIS without cocaine use	exoykedbqm(ctcoqhtlgi) = gztgxhheus agfwghizkl (jhtehnghlo ) View more
ACR2017	Not Applicable	Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis ANCA antibodies \| inflammatory markers \| haematology and biochemistry profiles	14	Cocaine-induced vasculitis	urgcpnytmm(bywukgjhcg) = kpztqmshjm zkgzowlvvv (pblfcdgjfd ) View more	Negative	06 Nov 2017
				Cocaine (Idiopathic ANCA vasculitis)	urgcpnytmm(bywukgjhcg) = mlldpdgylv zkgzowlvvv (pblfcdgjfd )
NCT00373880 (CTgov)	Phase 2	Cocaine-Related Disorders	26	Placebo+Cocaine (Placebo + 0mg Cocaine)	ytgpadgeuc(jnzttkckvz) = wqqwphgbnb oviypqphtc (vtoeyioaoe, pjplnicvnz - kopkmwcwoe) View more	-	11 Sep 2017
				Placebo+Cocaine (Placebo + 12mg Cocaine)	ytgpadgeuc(jnzttkckvz) = qpobnlbzzt oviypqphtc (vtoeyioaoe, giijswcyyg - kxmsyttfgk) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis